Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9158807rdf:typepubmed:Citationlld:pubmed
pubmed-article:9158807lifeskim:mentionsumls-concept:C0024198lld:lifeskim
pubmed-article:9158807lifeskim:mentionsumls-concept:C1457887lld:lifeskim
pubmed-article:9158807lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:9158807lifeskim:mentionsumls-concept:C0007732lld:lifeskim
pubmed-article:9158807lifeskim:mentionsumls-concept:C0597979lld:lifeskim
pubmed-article:9158807lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:9158807lifeskim:mentionsumls-concept:C0184511lld:lifeskim
pubmed-article:9158807lifeskim:mentionsumls-concept:C0332325lld:lifeskim
pubmed-article:9158807lifeskim:mentionsumls-concept:C0205369lld:lifeskim
pubmed-article:9158807lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:9158807lifeskim:mentionsumls-concept:C0868928lld:lifeskim
pubmed-article:9158807lifeskim:mentionsumls-concept:C0439858lld:lifeskim
pubmed-article:9158807pubmed:issue4lld:pubmed
pubmed-article:9158807pubmed:dateCreated1997-6-17lld:pubmed
pubmed-article:9158807pubmed:abstractTextWe present four cases of verified late Lyme borreliosis with persistent symptoms and positive serology despite repeated courses of high-dose intravenous penicillin G and/or cephalosporins (including cefoperazone). The patients were now treated with cefoperazone 2 g plus sulbactam 1 g bid iv for 14 days. At the end of treatment, patients were symptom free and have remained so for the following 12 months. By then, IgG against Borrelia burgdorferi had decreased. It is concluded that the addition of beta-lactamase inhibitors to intravenous treatment could be beneficial in Lyme disease refractory to conventional treatment.lld:pubmed
pubmed-article:9158807pubmed:languageenglld:pubmed
pubmed-article:9158807pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9158807pubmed:citationSubsetIMlld:pubmed
pubmed-article:9158807pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9158807pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9158807pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9158807pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9158807pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9158807pubmed:statusMEDLINElld:pubmed
pubmed-article:9158807pubmed:issn1076-6294lld:pubmed
pubmed-article:9158807pubmed:authorpubmed-author:KleinWWlld:pubmed
pubmed-article:9158807pubmed:authorpubmed-author:GasserRRlld:pubmed
pubmed-article:9158807pubmed:authorpubmed-author:DREWC ECElld:pubmed
pubmed-article:9158807pubmed:authorpubmed-author:PokanRRlld:pubmed
pubmed-article:9158807pubmed:authorpubmed-author:ReisingerEElld:pubmed
pubmed-article:9158807pubmed:authorpubmed-author:SedaaKKlld:pubmed
pubmed-article:9158807pubmed:authorpubmed-author:SeinostGGlld:pubmed
pubmed-article:9158807pubmed:authorpubmed-author:BerglöffJJlld:pubmed
pubmed-article:9158807pubmed:authorpubmed-author:HorwarthRRlld:pubmed
pubmed-article:9158807pubmed:issnTypePrintlld:pubmed
pubmed-article:9158807pubmed:volume1lld:pubmed
pubmed-article:9158807pubmed:ownerNLMlld:pubmed
pubmed-article:9158807pubmed:authorsCompleteYlld:pubmed
pubmed-article:9158807pubmed:pagination341-4lld:pubmed
pubmed-article:9158807pubmed:dateRevised2005-11-17lld:pubmed
pubmed-article:9158807pubmed:meshHeadingpubmed-meshheading:9158807-...lld:pubmed
pubmed-article:9158807pubmed:meshHeadingpubmed-meshheading:9158807-...lld:pubmed
pubmed-article:9158807pubmed:meshHeadingpubmed-meshheading:9158807-...lld:pubmed
pubmed-article:9158807pubmed:meshHeadingpubmed-meshheading:9158807-...lld:pubmed
pubmed-article:9158807pubmed:meshHeadingpubmed-meshheading:9158807-...lld:pubmed
pubmed-article:9158807pubmed:meshHeadingpubmed-meshheading:9158807-...lld:pubmed
pubmed-article:9158807pubmed:meshHeadingpubmed-meshheading:9158807-...lld:pubmed
pubmed-article:9158807pubmed:meshHeadingpubmed-meshheading:9158807-...lld:pubmed
pubmed-article:9158807pubmed:meshHeadingpubmed-meshheading:9158807-...lld:pubmed
pubmed-article:9158807pubmed:meshHeadingpubmed-meshheading:9158807-...lld:pubmed
pubmed-article:9158807pubmed:meshHeadingpubmed-meshheading:9158807-...lld:pubmed
pubmed-article:9158807pubmed:meshHeadingpubmed-meshheading:9158807-...lld:pubmed
pubmed-article:9158807pubmed:meshHeadingpubmed-meshheading:9158807-...lld:pubmed
pubmed-article:9158807pubmed:year1995lld:pubmed
pubmed-article:9158807pubmed:articleTitleCases of Lyme borreliosis resistant to conventional treatment: improved symptoms with cephalosporin plus specific beta-lactamase inhibition.lld:pubmed
pubmed-article:9158807pubmed:affiliationDepartment of Medicine, University of Graz, Austria.lld:pubmed
pubmed-article:9158807pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9158807pubmed:publicationTypeCase Reportslld:pubmed